EBMT Activity Survey 2017
683 Teams
41,100 Patients
45,418 Transplants
49 Countries

For internal use only.
For any other use, please contact Helen Baldomero for permission: helen.baldomero@usb.ch
# EBMT Activity Survey in 2017: Patient and transplant numbers

<table>
<thead>
<tr>
<th>Indication</th>
<th>Allogeneic HSCT</th>
<th>Autologous HSCT</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st allo/1st auto HSCT</td>
<td>17,155</td>
<td>23,945</td>
<td>41,100</td>
</tr>
<tr>
<td>Additional HSCT</td>
<td>1,126</td>
<td>3,192</td>
<td>4,318</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>18,281</strong></td>
<td><strong>27,137</strong></td>
<td><strong>45,418</strong></td>
</tr>
</tbody>
</table>

Teams: 683 (of 710)      Countries reporting: 49
EBMT Activity Survey in 2017: Donor type and stem cell source: all transplants

<table>
<thead>
<tr>
<th>Donor type</th>
<th>BM</th>
<th>PBSC</th>
<th>Cord</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-id sibling</td>
<td>1,420</td>
<td>4,411</td>
<td>33</td>
<td>5,864</td>
</tr>
<tr>
<td>Haplo-identical</td>
<td>708</td>
<td>1,981</td>
<td>n.a.</td>
<td>2,689</td>
</tr>
<tr>
<td>Other family</td>
<td>89</td>
<td>212</td>
<td>5</td>
<td>306</td>
</tr>
<tr>
<td>Syngeneic</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>21</td>
</tr>
<tr>
<td>Unrelated</td>
<td>1,492</td>
<td>7,579</td>
<td>330</td>
<td>9,401</td>
</tr>
<tr>
<td>Allogeneic</td>
<td>3,709</td>
<td>14,204</td>
<td>368</td>
<td>18,281</td>
</tr>
<tr>
<td>Autologous</td>
<td>112</td>
<td>27,022</td>
<td>3</td>
<td>27,137</td>
</tr>
</tbody>
</table>
EBMT Activity Survey 2017: Main indications

<table>
<thead>
<tr>
<th>Indication</th>
<th>Allogeneic 1&lt;sup&gt;st&lt;/sup&gt; HSCT</th>
<th>Autologous 1&lt;sup&gt;st&lt;/sup&gt; HSCT</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myeloid (AML, CML, MDS/MPN)</td>
<td>9,772</td>
<td>375</td>
<td>10,147</td>
</tr>
<tr>
<td>Lymphoid (ALL, CLL, HL, NHL)</td>
<td>4,630</td>
<td>8,781</td>
<td>13,411</td>
</tr>
<tr>
<td>Plasma cell disorder</td>
<td>385</td>
<td>12,692</td>
<td>13,077</td>
</tr>
<tr>
<td>Solid tumor</td>
<td>36</td>
<td>1,571</td>
<td>1,607</td>
</tr>
<tr>
<td>Non-malignant disorders</td>
<td>2,173</td>
<td>494</td>
<td>2,667</td>
</tr>
<tr>
<td>Bone marrow failure</td>
<td>802</td>
<td>1</td>
<td>803</td>
</tr>
<tr>
<td>Other</td>
<td>159</td>
<td>32</td>
<td>191</td>
</tr>
<tr>
<td>Total Patients</td>
<td>17,155</td>
<td>23,945</td>
<td>41,100</td>
</tr>
</tbody>
</table>
Allogeneic HSCT in Europe 2017
1st HSCT

- **AML**, 39%
- **ALL**, 16%
- **CML**, 12%
- **MPN**, 4%
- **MDS**, 12%
- **CLL**, 1%
- **HL**, 3%
- **PCD**, 2%
- **NHL**, 7.5%
- **BMF**, 5%
- **HG**, 4%
- **PID**, 3%
- **AID**, 0.1%
- **IDM**, 0.9%
- **Others**, 1%
- **Solid tumors**, 0.2%

Provided by the EBMT Activity Survey Office: not for publication
Autologous HSCT in Europe 2017
1st HSCT

- PCD, 53%
- NHL, 27%
- HL, 9%
- ALL/CLL, 0.4%
- Myeloid disorders, 2%
- Others, 0.1%
- AID, 2%
- NMD, 0.1%
- Other ST, 2%
- Breast, 0.1%
- Germinal tumors, 2%
- Soft tissue/Ewing, 1%
- Neuroblastoma, 2%

Provided by the EBMT Activity Survey Office: not for publication
HSCT Activity in Europe 1990-2017: Transplant type 1st HSCT

N. Patients

Year

0 5000 10000 15000 20000 25000 30000

90 92 94 96 98 00 02 04 06 08 10 12 14 16

Autologous  Allogeneic
HSCT Activity in Europe 1990-2017: Main indications: allogeneic 1st. HSCT
HSCT Activity in Europe 1990-2017: Main indications: autologous 1st. HSCT

- Leukemia
- NHL, HD, CLL
- PCD
- ST
- NMD
- Others

Year
HSCT Activity in Europe 1990-2017: donor origin: 1st. HSCT

- HLA identical sibling
- Haploidentical
- Unrelated
- Cord blood

Year: 1990 - 2017

Provided by the EBMT Activity Survey Office: not for publication
HSCT - rates in Europe 2017

N. allogeneic transplants per 10 million population

- 0 or no report
- 0.1 - 100
- 101 - 150
- 151 - 200
- 201 - 300
- > 300

Algeria, Iran, Iraq, Lebanon, Nigeria, South Africa, Tunisia

Jordan, Saudi Arabia

Israel
HSCT - rates in Europe 2017

N. autologous transplants per 10 million population

- 0 or no report
- 1 - 100
- 101 - 300
- 301 – 400
- 401 – 500
- > 500

- Algeria, Iran, Iraq, Jordan, Lebanon, Saudi Arabia, South Africa, Tunisia
- Israel

Provided by the EBMT Activity Survey Office: not for publication